Last reviewed · How we verify
Fludarabine plus Darbopoetin
Fludarabine inhibits DNA synthesis in leukemic cells while darbopoetin stimulates red blood cell production to counteract chemotherapy-induced anemia.
Fludarabine inhibits DNA synthesis in leukemic cells while darbopoetin stimulates red blood cell production to counteract chemotherapy-induced anemia. Used for Chronic lymphocytic leukemia (CLL).
At a glance
| Generic name | Fludarabine plus Darbopoetin |
|---|---|
| Sponsor | German CLL Study Group |
| Drug class | Combination chemotherapy with erythropoiesis-stimulating agent |
| Target | DNA synthesis pathway (fludarabine); erythropoietin receptor (darbopoetin) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Fludarabine is a purine analog that acts as a nucleotide antimetabolite, inhibiting ribonucleotide reductase and DNA polymerase to induce apoptosis in lymphoid malignancies. Darbopoetin alfa is an erythropoiesis-stimulating agent that binds to the erythropoietin receptor to increase hemoglobin levels and reduce transfusion requirements in patients experiencing chemotherapy-related anemia.
Approved indications
- Chronic lymphocytic leukemia (CLL)
Common side effects
- Myelosuppression
- Infection
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
Key clinical trials
- Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |